Last year, many companies in the cosmetic medical device industry achieved record-breaking performances. This year, their first-quarter sales have continued to grow, attracting significant attention. However, some companies have seen declines in operating and net profits, necessitating close monitoring of future trends.

According to industry reports on May 17th, the combined first-quarter sales of five listed cosmetic medical device companies—Classys, Jeisys Medical, Wontech, Ilooda, and VioL—totaled $105.8 million, a 26% increase compared to the same period last year. Except for Wontech, which saw a 2% decrease in sales, the others experienced growth ranging from 19% to 56%.

Jeisys Medical had the most significant sales growth, surging 56% from $20 million in Q1 2023 to $31.2 million this year, exceeding the $27.1 million consensus predicted by FnGuide.

Devices such as HIFU and RF recorded the highest sales, followed by consumables like cartridges and tips. Overseas markets are expanding, especially for RF devices like Potenza. The non-invasive RF device "Density" received pre-market approval in the US and is now being sold locally, with plans to enter the Chinese and Japanese markets.

Classys reported first-quarter sales of $36.8 million, exceeding the $35.3 million consensus. A company representative noted that orders for consumables from newly installed Shurink Universe and Volnewmer devices increased faster than expected. Consumables accounted for 52.6% of sales, while Classys medical devices made up 41.3%.

Experts suggest focusing on Classys' operating profit margin, which was 52.6% in the first quarter, higher than its competitors. Jeisys Medical had an 18% margin, Wontech 30%, and Ilooda 6%. Classys stated, "We expect the operating leverage effect from increased consumable sales, improved productivity, and controlled SG&A expenses throughout the year."

Ilooda and VioL saw sales increase by 21% and 19%, reaching $9.3 million and $8.2 million, respectively. Ilooda, with 80% of its sales from exports, plans to expand its overseas channels. Recently, it signed a distributor agreement with Infix for its pigment disorder treatment device, 'Lipat,' in Japan.

Wontech reported first-quarter sales of $20.1 million, a 2% decrease from last year. Its operating profit and net profit dropped by 38% and 36%. The company cited delayed sales recognition in Thailand and the US but noted steady growth in RF product tips like "Oligio," which accounted for 30.9% of Wontech's sales in 2024, the highest among its products.